Publications by authors named "C El Hasi"
Siglec-9 is a promising immune checkpoint molecule, and therapeutics targeting Siglec-9 have the potential to augment anti-tumor immunity. Here, we generated a bispecific antibody, named as aSE4-1-Fc, by fusing two distinct alpaca derived nanobodies, which can simultaneously target the extracellular Ig variable (V)-set domain and C2-set domains of murine Siglec-9 (also known as Siglec-E) with high affinity. In vivo studies showed that aSE4-1-Fc was better than its component antibodies in inhibiting tumor growth/metastasis, and Siglec-E blockade using aSE4-1-Fc generated protective anti-tumor T cell memory.
View Article and Find Full Text PDFArticle Synopsis
- This study investigates the characteristics and azole resistance mechanisms of Candida parapsilosis isolates in China.
- Out of 2318 isolates tested, 2.4% were resistant to fluconazole, especially prevalent among ICU patients, highlighting significant genetic clustering and transmission.
- Key mutations were identified, including Erg11Y132F, which contributes to resistance, along with others that play a role in increasing resistance levels and cross-resistance to different azoles.
Background: As the novel serum biomarkers, it has not been clearly clarified that the diagnostic accuracy of prostate health index (PHI) and prostate health index density (PHID) are superior to that of percentage free prostate-specific antigen (%fPSA) in detection of clinically significant prostate cancer (csPCa), especially in the gray zone. Therefore, this study aimed to compare the diagnostic value of PHI, PHID, and %fPSA for csPCa in the patients with prostate-specific antigen (PSA) >4 ng/mL and those with PSA within 4-10 ng/mL.
Methods: In this study, the serum samples and clinicopathological features were prospectively obtained from the patients who underwent prostate biopsy between September 2019 and December 2020.
Objective: This study was designed to explore the clinical characteristics, outcomes, and related influencing factors for asymptomatic patients with positive Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-Cov-2) nucleic acid test.
Methods: Clinical data of 1568 patients with positive SARS-Cov-2 nucleic acid test (SNAT) were collected retrospectively. The patients were assigned to an asymptomatic group and a symptomatic group according to the existence of clinical symptoms when they got positive result in nucleic acid test, and the clinical data of the two groups were analyzed and compared.
Objective: It aimed to analyze the epidemic situation of new coronary pneumonia (COVID-19) based on the epidemiological Markov model, and to study the clinical risk factors of the patients based on the patient's cardinal data and clinical symptoms.
Methods: A total of 500 patients with COVID-19 diagnosed by nucleic acid testing in the X hospital from January 2020 to May 2020 were collected. According to the severity of the disease, they were classified into general group (200 cases) and acute critical group (300 cases).